Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36608320

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2023 Apr 6
First author
Giesen N

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Giesen N
      type
      Author
    2. name
      Chatterjee M
      type
      Author
    3. name
      Scheid C
      type
      Author
    4. name
      Poos AM
      type
      Author
    5. name
      Besemer B
      type
      Author
    6. name
      Miah K
      type
      Author
    7. name
      Benner A
      type
      Author
    8. name
      Becker N
      type
      Author
    9. name
      Moehler T
      type
      Author
    10. name
      Metzler I
      type
      Author
    11. name
      Khandanpour C
      type
      Author
    12. name
      Seidel-Glaetzer A
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Giesen N
      type
      Author
    2. name
      Chatterjee M
      type
      Author
    3. name
      Scheid C
      type
      Author
    4. name
      Poos AM
      type
      Author
    5. name
      Besemer B
      type
      Author
    6. name
      Miah K
      type
      Author
    7. name
      Benner A
      type
      Author
    8. name
      Becker N
      type
      Author
    9. name
      Moehler T
      type
      Author
    10. name
      Metzler I
      type
      Author
    11. name
      Khandanpour C
      type
      Author
    12. name
      Seidel-Glaetzer A
      type
      Author
    bibliography ids
    1. nci-bib-913094af8963e69714ae7078
    book metadata
    content sha256
    3f5c5abfea32b466dc1e6114057f6727c095d3839ca3be5593c6aadadffb4746
    document type
    citation
    dois
    1. 10.1182/blood.2022017789
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:36608320
    immutable id
    pubmed:36608320@3f5c5abfea32b466dc1e6114057f6727c095d3839ca3be5593c6aadadffb4746
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    14
    name
    Blood
    nlm unique id
    7603509
    pages
    1685-1690
    volume
    141
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      36608320
      provenance
      batch id
      d370e99271168e8a8a13
      provider
      NCBI PubMed ESummary
      record sha256
      9a9c6d4c2994b306417c30004dc8bd8256e7a589eecce617dc409a4169b959dd
      response sha256
      f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
      retrieved at
      2026-09-09T23:48:13.005737+00:00
      publication date
      display
      2023 Apr 6
      precision
      day
      year
      2023
      publication types
      1. Clinical Trial, Phase II
      2. Multicenter Study
      3. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/36608320/
      title
      A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.

      Preserved source evidence · Not medical advice